Biopharmaceutical newcomer Intra-Cellular surged over 25% before the market opened! It is reported that Johnson & Johnson is in talks to acquire the company, reigniting a wave of Medical mergers and acquisitions.

Johnson & Johnson is in talks to acquire the biopharmaceutical company Intra-Cellular Therapies Inc., which focuses on treating central nervous system diseases, and both parties may reach an agreement as early as this week.

Zhitong Finance17:27

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires27minutes ago

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

WSJ55minutes ago

US stock outlook | Wall Street begins to discuss the possibility of interest rate hikes! The three major index futures collectively weakened; Intra-Cellular surged nearly 35% in pre-market trading! It will be acquired by Johnson & Johnson for billions.

Tesla fell 3% before the market opened, as the largest Retirement Fund in Europe liquidated its shares; the yield on the 10-year US Treasury is aiming for 5%! The Global bond market is in turmoil.

Futu News21:21

Johnson & Johnson (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for sale in the domestic market.

Johnson & Johnson (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for sale in the domestic market.

Zhitong Finance21:21

Top Premarket Gainers

MT Newswires21:12